Bioassays for evaluation of medical products derived from bacterial toxins

Current Opinion in Microbiology

Volumn 15, Issue 3, 2012, Pages 310-316

  Sesardic, Thea ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; TETANUS TOXOID;

ANTIBODY RESPONSE; BIOASSAY; DRUG POTENCY; DRUG SAFETY; EVALUATION; GEOMETRY; GRIP STRENGTH; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; LD 50; MEDICINE; NONHUMAN; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SEROLOGY; VACCINATION; VALIDATION STUDY;

ANIMALS; BACTERIAL TOXINS; BACTERIAL VACCINES; BIOLOGICAL ASSAY; CELL LINE; HUMANS;

BACTERIA (MICROORGANISMS);

EID: 84864067121     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2012.05.008     Document Type: Review

References (52)

1. Requirements for diphtheria, tetanus, pertussis and combined vaccines. WHO Expert Committee on Biological Standardisation. Fortieth report, Geneva, World Health Organisation, 1990 (WHO Technical Report Series, No. 800). Annex 2. To be replaced with Recommendations to assure the quality, safety and efficacy of diphtheria, tetanus and DTP combinations, WHO, October 2012.
2. Recommendations for diphtheria, tetanus, pertussis and combined vaccines (Amendments 2003). WHO Expert Committee on Biological Standardisation, Geneva, World Health Organisation, 2005 (WHO Technical Report Series No 927), Annex 5.
3. Coombes L., Stickings P., Tierney R., Rigsby P., Sesardic D. Development and use of a novel in vitro assay for testing of diphtheria toxoid in combination vaccines. J Immunol Methods 2009, 350:142-149.
4. Keller J.E. Overview of currently approved serological methods with a focus on diphtheria and tetanus potency testing. Procedia Vaccinol 2011, 5:192-199.
5. Assay of tetanus vaccine (adsorbed), general chapter 2.7.8 version 01/2011:20708. European Pharmacopoeia 2011, Council of Europe, Strasbourg, France. edn 7.
6. Assay of diphtheria vaccine (adsorbed), general chapter 2.7.6. European Pharmacopoeia 2011, Council of Europe, Strasbourg, France. edn 7.
7. Winsnes R., Sesardic D., Daas A., Terao E., Behr-Gross M.-E. Collaborative study on guinea pig serological model for the assay of acellular pertussis vaccines. Pharmeur Bio 2009, 1:27-40.
8. Stickings P., Rigsby P., Coombes L., Hockley J., Tierney R., Sesardic D. Animal refinement and reduction: alternative approaches for potency testing of diphtheria and tetanus vaccines. Procedia Vaccinol 2011, 5:200-212.
9. Botulinum toxin type A for injection. 07/2011:2113. European Pharmacopoeia 2011, Council of Europe, Strasbourg, France. edn 7.
10. McLellan K., Gaines Das R., Ekong T.A.N., Sesardic D. Therapeutic botulinum type A toxin: factors affecting potency. Toxicon 1996, 34:975-985.
11. Sesardic D., Leung T., Gaines Das R. Role of standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin. Biologicals 2003, 31:265-276.
12. Sesardic D., McLellan K., Ekong T.A.N., Gaines Das R. Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin. Pharmacol Toxicol 1996, 78:283-288.
13. Carli L., Montecucco C., Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve 2009, 40:374-380.
14. Torii Y., Goto Y., Takahashi M., Ishida S., Harakawa T., Sakamoto T., Kaji R., Ginnaga A. Quantitative determination of biological activity of botulinum toxins utilizing compound muscle action potentials (CMAP), and comparison of neuromuscular transmission blockage and muscle flaccidity among toxins. Toxicon 2010, 55:407-414.
15. Torii Y., Kiyota N., Sugimoto N., Mori Y., Goto Y., Harakawa T., Nakahira S., Ginnaga A. Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test. Toxicon 2011, 57:93-99.
16. Sesardic D., Jones R.G.A., Leung T., Alsop T., Tirney R. Detection of antibodies against botulinum toxins. Mov Disord 2004, 19:85-91.
17. Jones R.G.S., Alsop T.-A., Hull R., Tierney R., Rigsby P., Holley J., Sesardic D. Botulinum type A toxin neutralisation by specific IgG and its fragments: a comparison of mouse systemic toxicity and flaccid paralysis assays. Toxicon 2006, 48:246-254.
18. Gaines-Das R., Ochiai M., Douglas-Bardsley A., Asokanathan C., Horiuchi Y., Rigsby P., Corbel M., Xing D. Transferability of dermal temperature histamine sensitization test for estimation of pertussis toxin-like activity. Hum Vaccine 2009, 5:166-171.
19. Jensen S.E., Illigen K.E., Badsberg J.H., Hasløv K.R. Specificity and detection limit of a dermal temperature histamine sensitization test for absence of residual pertussis toxin in vaccines. Biologicals 2012, 40:36-40.
20. Recommendations to assure the quality, safety and efficacy of acellular pertussis vaccines. Adopted WHO EBCS October 2011. http://www.who.int/biologicals/areas/vaccines/apertussis/en/index.htm.
21. Casey W., Schmitt M., McFarland R., Isbrucker R., Levis J., Arciniega J., Descamps J., Finn T., Hendriksen C., Horiuchi Y., et al. Improving animal welfare and reducing animal use for human potency testing: state of the science and future directions. Procedia Vaccinol 2011, 5:33-46.
22. Horiuchi Y., Ochiai O., Kataoka M., Yamamoto A., Yuen C.-T., Asokanathan C., Corbel M., Kurata T., Xing D. Strategic approaches for developing alternative tests for safety and potency of vaccines. Procedia Vaccinol 2011, 5:156-163.
23. Ekong T.A.N., Feavers I., Sesardic D. Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A endopeptidase activity. Microbiology 1997, 143:3337-3347.
24. Joshi S.G. Detection of biologically active botulinum neurotoxin-A in serum using high-throughput FRET-assay. J Pharmacol Toxicol Methods 2012, 65:8-12.
25. Boyer A.E., Moura H., Woolfitt A.R., Kalb S.R., McWilliams L.G., Pavlopoulos A., Schmidt J.G., Barr J.R. From the mouse to the mass spectrometer: detection and differentiation of the endoproteinase activities of botulinum neurotoxins A-G by mass spectrometry. Anal Chem 2005, 77:3916-3924.
26. Kim Y.J., Baek J.H., Kim J.-H., Kim B.S., Rhie G., Yoo C.-K., Shin N.-R. Detection of botulinum neurotoxin type A by in vitro bioassay based on endopeptidase activity. J Bacteriol Virol 2010, 40:29-37.
27. Ruge D.R., Dunning F.M., Piazza T.M., Molles B.E., Adler M., Zeytin F.N., Tucker W.C. Detection of six serotypes of botulinum neurotoxin using fluorogenic reporters. Anal Biochem 2011, 411:200-209.
28. Titov A.A., Shilenko I.V., Morozov A.A., Yarkov S.P., Zlobin V.N. Development and optimization of immunoassays for the detection of botulinum toxins. Appl Biochem Microbiol 2012, 48:222-228.
29. Jones R.G.A., Ochiai M., Liu Y., Ekong T., Sesardic D. Development of improved SNAP25 endopeptidase immune-assays for botulinum type A and E toxins. J Immunol Methods 2008, 329:92-101.
30. Sesardic D., Gaines-Das R.E. Botulinum Toxin: Applying the 3Rs to Product Potency Testing 2009, N3CRs, pp. 1-8. http://www.nc3rs.org.uk/.
31. Adler E., et al. Current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. Report and Recommendation of the ZEBET Expert meeting. ALTA 2010, 38:315-330.
32. National Institute of Health. Report on the ICCVAM-NICEATM/ECVAM Scientific Workshop on Alternative Methods to Refine, Reduce or Replace the Mouse LD50 Assay for Botulinum Toxin Testing. NIH publication number 2008, 08-6416, Bethesda, MD.
33. Evans E.R., Skipper P.J.A., Shone C.C. An assay for botulinum toxin types A, B and F that requires both functional binding and catalytic activities within the neurotoxin. J Appl Microbiol 2009, 107:1384-1391.
34. Liu Y., Rigsby P., Sesardic D., Marks J.D., Jones R.G.A. A functional dual-coated (FDC) microtiter plate method to replace the Botulinum toxin LD50 test. Anal Biochem 2012, 425:28-35.
35. Rasetti-Escargueil C., Machado C., Preneta-Blanc R., Fleck R., Sesardic D. Enhanced sensitivity to botulinum type A neurotoxin of human neuroblastoma SH-SY5Y cells after differentiation onto mature neuronal cells. Botulinum J 2011, 4:30-34.
36. Pellett S., Tepp W.H., Toth S.I., Johnson E.A. Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination. J Pharmacol Toxicol Methods 2010, 61:304-310.
37. Pellett S., Du Z.-W., Pier C.L., Tepp W.H., Zhang S.-C., Johnson E.A. Sensitive and quantitative detection of botulinum neurotoxin in neurons derived from mouse embryonic stem cells. Biochem Biophys Res Commun 2011, 404:388-392.
38. Whitemarsh R.C.M., Stratham M.J., Chase L.G., Stankewich C., Tepp W.H., Johnson E.A., Pellett S. Novel applications of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection. Toxicol Sci 2012, 126:426-435.
39. Tegenge M.A., Böhnel H., Gessler F. Neurotransmitter vesicle release from human model neurons (NT2) is sensitive to botulinum toxin A. Cell Mol Neurobiol 2012, 1-9.
40. Kiris E., Nuss J.E., Burnett J.C., Kota K.P., Koh D.C., Wanner L.M., Torres-Melendez E., Bavari S. Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery. Stem Cell Res 2011, 6:195-205.
41. Sesardic D. Potency and safety assessment of vaccines and antitoxins: chapter 26. Use of Cell-based Assays 2007, 497-503. Wiley Press, Chichester. G. Stacey, J. Davies (Eds.).
42. Rasetti-Escargueil C., Jones R.G.A., Liu Y., Sesardic D. Measurement of botulinum types A, B and E neurotoxicity using the phrenic nerve-hemidiaphragm: improved precision with in-bred mice. Toxicon 2009, 53:503-511.
43. Rasetti-Escargueil C., Liu Y., Rigsby P., Jones R.G.A., Sesardic D. Phrenic nerve-hemidiaphragm as a highly sensitive replacement assay for botulinum toxin and antibodies identification. Toxicon 2011, 57:1008-1016.
44. Leung T., Corran P., Gee C., Ekong T.A.N., Sesardic D. Application of an in vitro endopeptidase assay for detection of residual toxin activity in tetanus toxoids. Advancing Science and Elimination of the Use of Laboratory Animals for Development and Control of Vaccines and Hormones. Developments in Biological Standardisation 2002, vol 111:335-340.
45. Kegel B., Behrensdorf-Nicol H.A., Bonifas U., Silberbach K., Klimek J., Krämer B., Weißer K. An in vitro assay for detection of tetanus neurotoxin activity: using antibodies for recognizing the proteolytically generated cleavage product. Toxicol In Vitro 2007, 2:1641-1649.
46. Behrensdorf-Nicol H.A., Bonifas U., Kegel B., Silberbach K., Krämer B., Weißer W. In vitro determination of tetanus toxicity by an endopeptidase assay linked to a ganglioside-binding step. Toxicol In Vitro 2010, 24:988-994.
47. Gomez S.R., Yuen C.-T., Asokanathan C., Douglas-Bardsley A., Corbel M.J., Coote J.G., Parton R., Xing D.K.L. ADP-ribosylation activity in pertussis vaccines and its relationship to the in vivo histamine-sensitisation test. Vaccine 2007, 25:3311-3318.
48. Yuen C.-T., Horiuchi Y., Asokanathan C., Cook S., Douglas-Bardsley A., Ochiai M., Corbel M., Xing D. An in vitro assay system as a potential replacement for the histamine sensitisation test for acellular pertussis based combination vaccines. Vaccine 2010, 28:3714-3721.
49. Isbrucker R.A., Bliu A., Prior F. Modified binding assay for improved sensitivity and specificity in the detection of residual pertussis toxin in vaccine preparations. Vaccine 2010, 28:2687-2692.
50. Xing D., Maes A., Behr-Gross M.E., Costanzo A., Daas A., Buchheit K.H. 2010 Collaborative study for the standardisation of the histamine sensitizing test in mice and the CHO cell-based assay for the residual toxicity testing of acellular pertussis vaccines. Pharmeur Bio Sci Notes 2010, 1:51-63.
51. Hoonakker M.E., Ruiterkamp N., Hendriksen C.F.M. The cAMP assay: a functional in vitro alternative to the in vivo histamine sensitization test. Vaccine 2010, 28:1347-1352.
52. Mizukami T., Masumi A., Momose H., Kuramitsu M., Takizawa K., Naito S., Maeyama J.-I., Yamaguchi K. An improved abnormal toxicity test by using reference vaccine-specific body weight curves and histopathological data for monitoring vaccine quality and safety in Japan. Biologicals 2009, 37:8-17.